LatestIP And Trademarks 29 October 2026
India Rejects Patent for TB Alliance's BPaL Regimen
India’s patent office denied TB Alliance’s BPaL combo for multi‑drug‑resistant TB after opposition from Eldred Tellis of Sankalp over access concerns. The ruling could delay the drug’s Indian launch, postponing a shorter treatment for patients.
India’s patent office rejected the TB Alliance’s BPaL combination therapy, a short‑course regimen for multi‑drug‑resistant tuberculosis. The decision follows pre‑grant opposition raised by Eldred Tellis of the advocacy group Sankalp, citing public‑health and accessibility worries.
- Patent denied for BPaL combo
- Opposition led by Sankalp representative
- Potential delay in Indian market launch, affecting patients needing faster treatment
Read the full report here.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.